Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
NewsPartner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. PLSE
stocks logo

PLSE

-
Add to WatchlistAdvanced Chart
$
0.000
0(0.000%)1D
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
1 Analyst Rating
up Image0
Wall Street analysts forecast PLSE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PLSE is 22.00 USD with a low forecast of 22.00 USD and a high forecast of 22.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
up Image0
Current: 15.340
sliders
Low
22.00
Averages
22.00
High
22.00
up Image0
Current: 15.340
sliders
Low
22.00
Averages
22.00
High
22.00
Oppenheimer
Suraj Kalia
Outperform
initiated
$22
2025-07-07
Reason
Oppenheimer
Suraj Kalia
Price Target
$22
2025-07-07
initiated
Outperform
Reason
Oppenheimer analyst Suraj Kalia initiated coverage of Pulse Biosciences with an Outperform rating and $22 price target. The company has developed nanosecond pulsed field ablation technology and preliminary evidence suggests a better safety and efficacy profile versus traditional treatments in key applications like thyroid ablation, the analyst tells investors in a research note. The firm says Pulse has multiple shots on goal and an experienced CEO.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Pulse Biosciences Inc (PLSE.O) is -13.46, compared to its 5-year average forward P/E of -9.04. For a more detailed relative valuation and DCF analysis to assess Pulse Biosciences Inc 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-9.04
Current PE
-13.46
Overvalued PE
-1.76
Undervalued PE
-16.32

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
118.00
Current PS
431.43
Overvalued PS
345.43
Undervalued PS
-109.43

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

PLSE News & Events

Events Timeline

(ET)
2025-03-27
16:17:53
Pulse Biosciences reports Q4 EPS (31c) vs. (21c) last year
select
2025-01-10 (ET)
2025-01-10
07:22:01
Pulse Biosciences announces Paul LaViolette as CEO
select
2024-12-17 (ET)
2024-12-17
07:19:01
Pulse announces publication of nano-PFA Cardiac Surgical System data
select
Sign Up For More Events
Sign Up For More Events

News

Preview
1.0
08-01Newsfilter
Pulse Biosciences To Present at the 45th Canaccord Genuity Annual Growth Conference

  • Company Presentation Announcement: Pulse Biosciences, Inc. will present at the 45th Canaccord Genuity Annual Growth Conference in Boston on August 13, 2025, with a live and recorded webcast available on their investor website.

  • Technology Overview: The company specializes in bioelectric medicine, utilizing its proprietary CellFX® nsPFA™ technology to non-thermally ablate cells while preserving surrounding tissue, aiming to improve healthcare outcomes in areas like atrial fibrillation treatment.

Preview
4.0
07-07Benzinga
Oppenheimer Initiates Coverage On Pulse Biosciences with Outperform Rating, Announces Price Target of $22

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, providing real-time intelligence to help them succeed in the stock market.

  • Community and Exclusivity: Joining Benzinga Pro connects users with over 10,000 serious traders and grants access to exclusive stories and insights from Benzinga reporters.

Preview
5.0
06-17NASDAQ.COM
Insider Sale: Chief Technology Officer of $PLSE Sells 15,000 Shares

  • Insider Trading Activity: Darrin Uecker, CTO of $PLSE, sold 15,000 shares for approximately $245,999, representing about 9.8% of his holdings, leaving him with 137,872 shares. In the past six months, there have been two insider sales and no purchases of $PLSE stock.

  • Institutional Investor Movements: In the latest quarter, 41 institutional investors increased their positions in $PLSE, while 39 reduced theirs, indicating mixed sentiment among institutional stakeholders.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Pulse Biosciences Inc (PLSE) stock price today?

The current price of PLSE is 15.34 USD — it has increased 0.59 % in the last trading day.

arrow icon

What is Pulse Biosciences Inc (PLSE)'s business?

Pulse Biosciences, Inc. is a bioelectric medicine company. The Company’s CellFX Nanosecond Pulsed-Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. It is pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation (AF) and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers, such as surgical soft tissue ablation. Its nsPFA Percutaneous Electrode System consists of a disposable, percutaneous, needle electrode for use with its CellFX Console. Its surgical cardiac ablation clamp is designed for use by cardiac surgeons during the surgical treatment of AF. The CellFX Console is a tunable, software-enabled, console-based platform, designed to accommodate the clinical workflow preferred by physicians. It is also developing a Nanosecond PFA 360-degree Cardiac Catheter System.

arrow icon

What is the price predicton of PLSE Stock?

Wall Street analysts forecast PLSE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PLSE is 22.00 USD with a low forecast of 22.00 USD and a high forecast of 22.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Pulse Biosciences Inc (PLSE)'s revenue for the last quarter?

Pulse Biosciences Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Pulse Biosciences Inc (PLSE)'s earnings per share (EPS) for the last quarter?

Pulse Biosciences Inc. EPS for the last quarter amounts to -0.25 USD, increased 38.89 % YoY.

arrow icon

What changes have occurred in the market's expectations for Pulse Biosciences Inc (PLSE)'s fundamentals?

The market is revising No Change the revenue expectations for Pulse Biosciences, Inc. (PLSE) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -7.31%.
arrow icon

How many employees does Pulse Biosciences Inc (PLSE). have?

Pulse Biosciences Inc (PLSE) has 75 emplpoyees as of August 07 2025.

arrow icon

What is Pulse Biosciences Inc (PLSE) market cap?

Today PLSE has the market capitalization of 1.03B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free